Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

55.78 +1.37 (+2.52%)
Streaming Delayed Price Updated: 10:55 AM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 69,613
Open 54.81
Bid (Size) 55.70 (4)
Ask (Size) 55.91 (1)
Prev. Close 54.41
Today's Range 54.42 - 55.87
52wk Range 27.58 - 67.66
Shares Outstanding 47,907,411
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These Three Biotech Stocks Are Trading At A Discount
Investors exposed to the biotech sector have seen mixed results this year. 
Via Talk Markets
Exploring growth characteristics of AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH).
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock. 
Via Chartmill

Performance

YTD
+97.80%
+97.80%
1 Month
+23.46%
+23.46%
3 Month
+4.01%
+4.01%
6 Month
+6.65%
+6.65%
1 Year
+90.70%
+90.70%

More News

Read More
Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
Via ACCESSWIRE
Evaluating NASDAQ:AMPH for Growth Investment Opportunities.
Via Chartmill
Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade
Via Investor's Business Daily
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Via ACCESSWIRE
Recap: Amphastar Pharma Q3 Earnings
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023
Via ACCESSWIRE
Earnings Preview For Amphastar Pharma
Via Benzinga
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Via InvestorPlace
Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade
Via Investor's Business Daily
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023
Via ACCESSWIRE
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
Via Investor's Business Daily
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
Via Investor's Business Daily
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
Via Investor's Business Daily
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
Via ACCESSWIRE
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why
Via Talk Markets
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.